Oddity Tech Just Beat Earnings — And Jumped From Beauty to Telehealth
TL;DR
Quick Summary
- Oddity Tech beat Q3 2025 expectations with ~24% revenue growth, higher margins, and raised full‑year guidance.
- The company launched Methodiq, an AI‑driven telehealth dermatology platform that pushes it beyond beauty into medical-grade skincare.
- Strong cash, fat margins, and a data-heavy DTC model give Oddity room to invest, but volatility and execution risk stay high.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
